PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer.-Reference-Cited by-同舟云学术

PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:TPS6097-TPS6097
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Evans Mererid¹,Knott Sarah²,Hurt Chris²,Patterson Joanne³,Robinson Max⁴,Hutcheson Kate A.⁵,Nixon Lisette⁶,Beasley Matthew⁷,Lee Jonny⁸,Wade Wendy⁹,Palaniappan Nachi¹⁰,Simon Christian¹¹,Powell Ned¹²,Greenhalf William¹³,Jones Terry¹³

Affiliation:

1. Velindre NHS Trust, Cardiff, United Kingdom;

2. Centre for Trials Research, Cardiff University, Cardiff, United Kingdom;

3. Newcastle University, Newcastle upon Tyne, United Kingdom;

4. Newcastle University, Newcastle-upon-Tyne, United Kingdom;

5. The University of Texas MD Anderson Cancer Center, Houston, TX;

6. Cardiff University, Cardiff, United Kingdom;

7. Bristol Haematology and Oncology Centre, Bristol, United Kingdom;

8. Mount Vernon Cancer Centre, London, United Kingdom;

9. NISCHR CRC South East Wales Research Network, Cardiff, United Kingdom;

10. Velindre Cancer Centre, Cardiff, Wales;

11. CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland;